AstraZeneca (AZN 7.39%) fell over 8% ahead of the opening bell after a late-stage clinical trial for its heart disease drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results